Monıtorıng Glucocortıcoıd Treatment In Patıents Followed In Rheumatology Clınıc

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-02-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Hypothesis 1: A reduction in side effects is achieved with monitoring glucocorticoid treatment by using the Glucocorticoid Toxicity Index (GTI) in patients using glucocorticoids.

Hypothesis 2: Monitoring treatment by using GTI in patients using glucocorticoids causes a decrease in glucocorticoid toxicity and an increase in the quality of life of patients.

Hypothesis 3: With the involvement of the clinical pharmacist in the multidisciplinary team in patients using glucocorticoids, the drug-related problems of the patients are detected and prevented.

The aim of this study was to evaluate the glucocorticoid treatment of patients with RA, SLE and vasculitis treated with glucocorticoids prospectively by a multidisciplinary team with GTI. In addition, it was aimed to identify and prevent drug-related problems by reviewing all drugs used in these patients by the clinical pharmacist.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy and Safety of Growth Hormone Treatment in Juvenile Idiopathic Arthritis

NCT00420251

Juvenile Idiopathic Arthritis Still Disease, Juvenile-Onset

COMPLETED PHASE3

The Risk of Adrenal Insufficiency and Cushing Syndrome Associated With Glucocorticoid Therapy in People With Chronic Inflammatory Diseases

NCT03575247

Adrenal; Insufficiency Gluccorticoid-Induced Cushing; Syndrome or Disease, Glucocorticoid-Induced

COMPLETED

Hydrocortisone and Placebo in Patients With Symptoms of Adrenal Insufficiency After Cessation of Glucocorticoid Treatment

NCT05193396

Adrenal Insufficiency Polymyalgia Rheumatica (PMR) Giant Cell Arteritis (GCA)

RECRUITING PHASE4

Growth Hormone Feedback to Insulin-like Growth Factor-I (IGF-1) and Oral Glucose Tolerance Test (OGTT)

NCT00915954

Acromegaly Type 2 Diabetes Mellitus

COMPLETED NA

Inter-Assay Growth Hormone and IGF-I Variability

NCT00638287

Acromegaly Growth Hormone Deficiency

WITHDRAWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In this study, the side effects of glucocorticoids used by patients will be evaluated using the Glucocorticoid Toxicity Index (GTI) index. This index includes areas for commonly recognized adverse events as a result of cumulative steroid exposure. It is weighted and measures both worsening and improvement. Scores range from -346 to 439 with cumulative worsening score relating to an increase in GC toxicity burden. "-" points indicate improvement, "+" points indicate worsening. The higher the patient's burden of glucocorticoid toxicity, the higher his score.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glucocorticoids Toxicity Rheumatoid Arthritis Vasculitis Systemic Lupus Erythematosus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RA, SLE, and vasculitis patients who have just started glucocorticoid treatment

No interventions assigned to this group

RA, SLE and vasculitis patients receiving glucocorticoid treatment for the last 2 years

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years and over
* Individuals who have received glucocorticoid treatment for RA, SLE or vasculitis in the last 2 years or at current admission.
* Patients approved by the physician to participate in the study
* Patients giving written consent